Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy: OCT Angiography Findings and Risk Factors

Table 1

Demographics and clinical characteristics of study patients.

	Total patients (n = 106)	Group A (n = 29)	Group B (n = 77)
Eyes, n (%)	108 (100)	31 (28.70)	77 (71.30)
Mean age, years	48.45 (9.13)	52.28 (6.87)	46.78 (9.45)	<0.001
Male, n (%)	79 (74.53)	20 (68.97)	59 (76.62)	0.578
HTN, n (%)	16 (15.09)	7 (24.14)	9 (11.69)	0.196
DM, n (%)	6 (5.66)	0 (0.00)	6 (7.79)	0.282
BCVA, logMAR
Initial	0.275 (0.279)	0.342 (0.365)	0.248 (0.233)	0.192
Final	0.167 (0.176)	0.206 (0.188)	0.151 (0.170)	0.158
Follow-up duration, months	35.56 (37.75)	51.48 (47.42)	29.14 (31.21)	0.006
Recurrence, n (%)				0.032
Recurrence	48 (44.44)	19 (61.29)	29 (37.66)
No recurrence	60 (55.56)	12 (38.71)	48 (62.34)
Chronicity, n (%)				0.156
Yes	80 (74.07)	26 (83.87)	54 (70.13)
No	28 (25.93)	5 (16.13)	23 (29.87)
Treatment, n (%)
Anti-VEGF	73 (67.59)	22 (70.97)	51 (66.23)	0.592
PDT or focal laser	55 (50.93)	16 (51.61)	37 (48.05)	0.903

Data are presented as mean (standard deviation) unless otherwise indicated. Student’s t-test; chi-squared test; Wilcoxon rank-sum test. HTN, hypertension; DM, diabetes mellitus; BCVA, best-corrected visual acuity; logMAR, logarithm of minimal angle of resolution; anti-VEGF, antivascular endothelial growth factor; PDT, photodynamic therapy.